Corcept Therapeutics (NASDAQ:CORT – Get Free Report) and Gelteq (NASDAQ:GELS – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.
Insider & Institutional Ownership
93.6% of Corcept Therapeutics shares are held by institutional investors. 20.5% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and price targets for Corcept Therapeutics and Gelteq, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Corcept Therapeutics | 0 | 0 | 5 | 0 | 3.00 |
Gelteq | 0 | 0 | 0 | 0 | 0.00 |
Earnings & Valuation
This table compares Corcept Therapeutics and Gelteq”s gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Corcept Therapeutics | $675.04 million | 8.75 | $106.14 million | $1.24 | 45.17 |
Gelteq | N/A | N/A | N/A | N/A | N/A |
Corcept Therapeutics has higher revenue and earnings than Gelteq.
Profitability
This table compares Corcept Therapeutics and Gelteq’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Corcept Therapeutics | 22.35% | 24.54% | 20.24% |
Gelteq | N/A | N/A | N/A |
Summary
Corcept Therapeutics beats Gelteq on 9 of the 9 factors compared between the two stocks.
About Corcept Therapeutics
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
About Gelteq
Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.